Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination (Q47431246)

16 January 2018

title

Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination (English)

1 reference

16 January 2018

0 references

Zhenwu Luo

1

1 reference

16 January 2018

Li Ren

2

1 reference

16 January 2018

Yang Zheng

3

1 reference

16 January 2018

Zhi Qi

4

1 reference

16 January 2018

Hua Liang

5

1 reference

16 January 2018

Yong Liu

6

1 reference

16 January 2018

Kunxue Hong

7

1 reference

16 January 2018

Yiming Shao

8

1 reference

16 January 2018

language of work or name

English

0 references

publication date

27 June 2012

1 reference

16 January 2018

published in

Vaccine

1 reference

16 January 2018

volume

30

1 reference

16 January 2018

issue

36

1 reference

16 January 2018

page(s)

5316-5323

1 reference

16 January 2018

The Renaissance in HIV Vaccine Development — Future Directions

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

7 January 2021

Polyvalent AIDS Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Accelerating HIV vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

The challenge of HIV-1 subtype diversity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

HIV-1 vaccine development after STEP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Toward an antibody-based HIV-1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Preparing for the availability of a partially effective HIV vaccine: some lessons from other licensed vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Simple subtyping assay for human immunodeficiency virus type 1 subtypes B, C, CRF01-AE, CRF07-BC, and CRF08-BC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

GP120: target for neutralizing HIV-1 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Structure of an unliganded simian immunodeficiency virus gp120 core

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Conservation of human immunodeficiency virus type 1 gp120 inner-domain sequences in lentivirus and type A and B retrovirus envelope surface glycoproteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Conservation of the Human Immunodeficiency Virus Type 1 gp120 V1/V2 Stem/Loop Structure in the Equine Infectious Anemia Virus (EIAV) gp90

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

A conservative domain shared by HIV gp120 and EIAV gp90: implications for HIV vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Electroporation delivery of DNA vaccines: prospects for success

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

The emerging role of innate immunity in protection against HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Early events in B cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Differentiation of effector CD4 T cell populations (*)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.053

10.1016/J.VACCINE.2012.06.053

7 January 2021

Identifiers

DOI

1 reference

16 January 2018

1 reference

16 January 2018